Li-Fraumeni syndrome is a rare cancer predisposition syndrome characterized by a high lifetime risk of developing different tumors including sarcomas, breast cancer, brain tumors, leukemia, and adrenal cortical carcinomas and is associated with germline m u t a t i o n s i n t h e T P 5 3 gene. 1,2 An annual surveillance program including whole-body magnetic resonance imaging (WB-MRI) potentially benefits these patients.
Methods | All patients identified as TP53 mutation carriers visiting our institute between October 2011 and July 2016 participated in the surveillance program. The Netherlands Cancer Institute considers this program as standard of care in these patients. A 12 minute WB-MRI scan protocol consisted of noncontrast T1-weighted and T2-STIR (short τ inversion recovery) series in the coronal plane and a whole body diffusion DWIBS (diffusion-weighted whole-body imaging with background body signal suppression) series scanned in the axial plane and reconstructed in the coronal plane. The number of abnormal findings requiring subsequent diagnostic testing in the first surveillance round was counted, with the resulting rate of true malignancies and false-positive findings.
Results | Fifty-six patients identified as TP53 mutation carriers were included in the surveillance program; 34 patients (61%) were women and 27 patients (48%) had a prior history of malignancy. Thirty-two abnormal findings were detected in 24 patients, giving rise to additional imaging or referral in all 24 patients ( Figure 1 and Figure 2 ).
Four of these abnormal findings were malignant (12.5%; 95% CI, 1.0%-24.0%), whereas 28 of the abnormal findings were false positives (87.5%; 95% CI, 76.0%-99.0%). One woman (age 66 years) was diagnosed with early-stage breast cancer visible on breast MRI and WB-MRI, and she was treated successfully. Another woman (age 38 years) had locoregional breast cancer recurrence diagnosed with WB-MRI and was also treated successfully without further evidence of disease activity since. A third woman (age 33 years) had a solitary liver metastasis after prior breast cancer. She received metastasectomy and repetitive lines of systemic treatment, but she died 30 months later. Finally, another woman (age 61 years) showed evidence of chronic lymphatic leukemia without need for treatment 3 years after diagnosis.
Twenty-six of 28 false-positive findings were detected by WB-MRI (93%). Detailed MRI and ultrasonography com- Discussion | The initial round of our annual surveillance program in patients identified as TP53 mutation carriers detected malignancies in approximately 7% of patients. This detection rate comes at the expense of many false-positive findings and additional diagnostic procedures in almost half of the patients. The high frequency of incidental findings at the first surveillance is well known from other screenings studies.
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Given the short follow-up, it is uncertain whether detecting asymptomatic malignancies will improve the prognosis of these patients. Extending the number of screened individuals, screening episodes, and follow-up time in the LiFe-Guard study and combining our data with other cohorts of TP53 mutation carriers in a meta-analysis will provide additional insight into the value of a surveillance program in this population. In addition, the LiFe-Guard study is currently collecting data on patient reported outcomes regarding the perceived benefits and limitations of a surveillance program including cancer worries. 
